AIR QUALITY RESEARCH LTD
Company number 06743036 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: AIR QUALITY RESEARCH LTD
1. Financial Health Score: D+
Explanation: While the company has achieved a dramatic recovery from its critically ill state in 2023, it now resembles a patient who has survived a serious illness but is left with virtually no muscle mass. The near-elimination of £113k in creditors is remarkable, but the company now operates as a minimal shell with only £21 in assets. The going concern uncertainty flagged by directors is the equivalent of a "do not resuscitate" warning on a medical chart – survival is possible, but far from guaranteed.
2. Key Vital Signs
| Vital Sign | 2025 | 2023 | Trend | Interpretation |
|---|---|---|---|---|
| Fixed Assets | £0 | £27,672 | ⬇ Severe decline | The company has divested or written off all long-term assets – the equivalent of losing all major organs |
| Current Assets | £21 | £410 | ⬇ Decline | Negligible liquidity – barely enough for a cup of coffee, let alone operating expenses |
| Creditors (< 1 Year) | £0 | (£113,382) | ⬆ Massive improvement | The most dramatic symptom change – near-total elimination of short-term debt |
| Creditors (> 1 Year) | £0 | (£967) | ⬆ Cleared | Long-term debt extinguished |
| Accruals & Deferred Income | (£721) | (£144) | ⬇ Increase | Small increase in obligations – relatively minor |
| Net Assets | (£700) | (£86,411) | ⬆ Massive improvement | Moved from deep insolvency to near-breakeven |
| Shareholders' Funds | (£700) | (£86,411) | ⬆ Improvement | Negative equity remains, but dramatically reduced |
| Employees | 3 | 3 | ➡ Stable | Minimal but consistent workforce |
Historical Trajectory (Net Assets)
| Year | Net Assets | Health Status |
|---|---|---|
| 2019 | £44,690 | ✅ Healthy |
| 2020 | £27,332 | ⚠️ Declining |
| 2021 | (£14,548) | 🔴 Insolvent |
| 2022 | (£69,001) | 🔴 Severely distressed |
| 2023 | (£86,411) | 🔴 Critical condition |
| 2025 | (£700) | ⚠️ Stabilised but fragile |
3. Diagnosis
What the Financial Data Reveals
The Near-Death Experience (2019-2023) The company experienced a catastrophic financial deterioration between 2019 and 2023. Net assets plummeted from a healthy £44,690 to a deeply negative £86,411 – a swing of over £130,000 into the red. This represents severe haemorrhaging of financial resources, with liabilities overwhelming assets by a ratio of more than 5:1 at the 2023 nadir.
The Dramatic Recovery (2023-2025) The most striking feature is the near-complete elimination of £113,382 in creditors due within one year, dropping to zero. This is the financial equivalent of a patient having a massive tumour removed overnight. However, such dramatic changes warrant scrutiny:
- Possible explanations: Debt forgiveness, restructuring, transfer to related parties, or a formal arrangement with creditors
- Concerning aspect: The fixed assets also disappeared (£27,672 to £0), suggesting asset disposals or write-offs
- The company has essentially been "gutted" – liabilities cleared, but also stripped of operating capacity
Going Concern Warning The directors have explicitly identified "material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern." This is the financial equivalent of a doctor noting "grave prognosis" on a patient's chart. While they conclude the going concern basis remains appropriate, this is a significant red flag.
Current State: The Empty Shell With only £21 in current assets, zero fixed assets, and minimal liabilities, the company resembles a dormant organism. It is technically in better shape than 2023 (near-zero net liabilities versus -£86k), but it has no visible means of generating revenue. The average employee count of 3 suggests some activity, but the balance sheet shows no working capital to support operations.
Share Capital Anomaly Share capital stands at £185.31 – a peculiarly specific and minimal figure. Combined with negative reserves of £700, the total equity position is technically insolvent, though marginally so.
4. Recommendations
Immediate Actions (Urgent)
-
Clarify the Liability Clearance: Obtain full disclosure on how £113k+ in short-term creditors was eliminated. If this involved debt forgiveness or a voluntary arrangement, ensure all legal and tax implications are properly addressed. This is like understanding what medication cured the patient – the side effects may be significant.
-
Address Going Concern Uncertainty: The directors' statement is a red flag for stakeholders. Prepare detailed cash flow projections and a viability statement demonstrating how the company will meet its obligations for at least 12 months. Without this, the company risks being prescribed a terminal diagnosis by creditors or regulators.
-
Rebuild Working Capital: With only £21 in current assets, the company cannot operate without external funding. Identify and secure funding sources – whether from shareholders (Mr Kukla holds 50-75% control), related entities, or external lenders.
Medium-Term Actions
-
Strategic Direction Assessment: As a research and development company (SIC 72190) with no visible assets, clarify the business model. Is the company continuing R&D activities? Are there intangible assets not reflected on the balance sheet? Are there contracts or grant funding that sustain the 3 employees?
-
Consider Capital Injection: Mr Kukla, as the majority shareholder, should consider whether a capital injection is appropriate to restore positive net assets and provide working capital. The current negative equity of £700 is trivial and could easily be rectified.
-
Review Filing Status: The company has changed its accounting reference date from November to May (this filing covers an 18-month period). Ensure this change was properly documented and that future filings remain timely.
Long-Term Actions
-
Determine Viability: Fundamentally assess whether the company has a sustainable business model. If the R&D activities have concluded or are not generating returns, consider whether the company should be wound up voluntarily rather than lingering in a zombie state.
-
Stakeholder Communication: Given the dramatic balance sheet changes, proactively communicate with any remaining stakeholders, including employees, about the company's future plans and financial stability.
Risk Assessment
| Risk Category | Level | Notes |
|---|---|---|
| Insolvency | 🟡 Medium | Net liabilities minimal (£700), but no assets to meet obligations |
| Going Concern | 🔴 High | Directors have flagged material uncertainty |
| Operational | 🔴 High | No visible working capital or assets |
| Compliance | 🟢 Low | Filings are current and on time |
| Governance | 🟡 Medium | Majority control by single PSC; 4 directors provide oversight |
Prognosis
The patient has survived a critical illness but remains in a fragile state of remission. The elimination of £113k in liabilities is remarkable, but the resulting entity has been stripped to the bone. With no fixed assets, negligible current assets, and an explicit going concern warning, the company's survival depends entirely on whether it can rebuild operating capacity and generate revenue. The presence of 3 employees and continued active status suggests intention to continue, but the balance sheet offers no evidence of how this will be funded.
The next 12-18 months are critical. If the company can secure funding and resume meaningful R&D activity, recovery is possible. If not, the current minimal state may simply be a slow-motion path toward dissolution.